BOSTON, MA—Patients with significant symptomatic degenerative mitral regurgitation (MR) who had complex anatomy making them ineligible for inclusion in the CLASP IID trial can be treated safely and ...

In a session at TCT 2014, two surgeons squared off over the proposal that catheter-based mitral valve therapies for mitral regurgitation (MR) will have an important clinical role in the future.

BOSTON -- The Pascal device for edge-to-edge mitral valve repair was as safe and effective as the MitraClip device, the pivotal CLASP IID trial showed. In a pre-specified interim analysis of the first ...

Mitral valve prolapse (MVP) is a common congenital abnormality of the heart that can cause severe complications such as arrhythmias, heart failure, and sudden cardiac death. To date, the causes of MVP ...

MValve Technologies Ltd announced today the first human implantation of its catheter based transapical mitral valve replacement system. The procedure was completed successfully at the University ...

In another first in cardiology, Apollo Hospitals, Chennai, performed India’s first fourth generation (G4) transcatheter mitral valve repair. Dr Sai Satish, senior interventional cardiologist, Apollo ...

MINNEAPOLIS, May 8, 2024 /PRNewswire/ -- 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has ...

IRVINE, Calif.--(BUSINESS WIRE)--CardiAQ Valve Technologies (CardiAQ), a leader in the field of Transcatheter Mitral Valve Implantation (“TMVI”), announced today that the European Patent Office Legal ...

IRVINE, Calif.--(BUSINESS WIRE)--CardiAQ Valve Technologies (CardiAQ), today announced that it has received a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to ...